289 related articles for article (PubMed ID: 6709108)
21. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
[TBL] [Abstract][Full Text] [Related]
22. [Pneumonia caused by Salmonella in a patient with myeloma].
Fernández P; Roldán V; García MC; Gil MT; Rivas C
Sangre (Barc); 1995 Jun; 40(3):234-5. PubMed ID: 7570286
[No Abstract] [Full Text] [Related]
23. [Recent therapy for refractory myeloma].
Togawa A
Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
[TBL] [Abstract][Full Text] [Related]
24. Vindesine in refractory multiple myeloma.
van der Lelie H; Monasch E; Pegels HG; von dem Borne AE
Cancer; 1986 Jan; 57(2):226-9. PubMed ID: 3942957
[TBL] [Abstract][Full Text] [Related]
25. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
Wutke K; Anger G
Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459
[TBL] [Abstract][Full Text] [Related]
26. Vindesine, carmustine, doxorubicin, and prednisone (EBAP) in recurrent lymphomas: a Southwest Oncology Group study.
Weick JK; Jones SE; Grozea PN; Fabian CJ; Dixon DO
Cancer Treat Rep; 1984; 68(7-8):963-7. PubMed ID: 6744347
[TBL] [Abstract][Full Text] [Related]
27. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF
Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
[No Abstract] [Full Text] [Related]
29. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy].
Shimokawa T; Kajiguchi T; Saito M; Kojima Y; Takeyama H
Gan To Kagaku Ryoho; 2003 Feb; 30(2):251-4. PubMed ID: 12610874
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
[No Abstract] [Full Text] [Related]
31. Vindesine therapy in melphalan-resistant multiple myeloma.
Houwen B; Ockhuizen T; Marrink J; Nieweg HO
Eur J Cancer (1965); 1981 Feb; 17(2):227-32. PubMed ID: 7262159
[No Abstract] [Full Text] [Related]
32. Thalidomide for the treatment of leptomeningeal multiple myeloma.
Yutaka H; Mariko Y; Shinichiro O; Kunihiko M; Yusuke T; Yasuo I
Eur J Haematol; 2006 Apr; 76(4):358-9. PubMed ID: 16519710
[No Abstract] [Full Text] [Related]
33. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
[TBL] [Abstract][Full Text] [Related]
34. Prednisone pulse therapy for refractory myeloma.
Alexanian R; Yap BS; Bodey GP
Blood; 1983 Sep; 62(3):572-7. PubMed ID: 6882916
[TBL] [Abstract][Full Text] [Related]
35. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
[No Abstract] [Full Text] [Related]
36. [Combination chemotherapy in Alkeran-resistant myelomatosis].
Kjølseth I; Wisløff F; Godal HC
Tidsskr Nor Laegeforen; 1984 May; 104(13):873-4. PubMed ID: 6463973
[No Abstract] [Full Text] [Related]
37. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
[TBL] [Abstract][Full Text] [Related]
38. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
[TBL] [Abstract][Full Text] [Related]
39. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
[TBL] [Abstract][Full Text] [Related]
40. Combination chemotherapy versus melphalan and prednisone in multiple myeloma.
Gruber A; Osby E
Chemioterapia; 1987 Jun; 6(2 Suppl):725-6. PubMed ID: 3509531
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]